IP Library Granted Patent US 9,364,585
Granted Patent B2
US 9,364,585 · App. 13/709,815 · Granted Jun 14, 2016

Methods for collecting and using placenta cord blood stem cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,364,585
App. No.
13/709,815
Granted
Jun 14, 2016
Kind
B2
Abstract

An innovative method of collecting cord blood stem cells from an isolated mammalian non-exsanguinated or partially exsanguinated placenta by placental perfusion is described and also an easy method for safe long duration cold storage of the placenta. Placental perfusion can include perfusing the isolated placenta with a pulsatile flow of perfusion solution, for example, using a pulsatile or peristaltic pump or device. The stem cells can then be isolated from the perfusate. Significantly increased amounts of CD133+ stem cells can be collected from the perfusate. The perfusion solution can include an anticoagulant. The isolated mammalian placenta need not be treated with an anticoagulant prior to perfusing. The isolated placenta can be free from an anticoagulant prior to perfusing.

Claims (33)

1. A method for treating a mammal comprising a damaged tissue, comprising:

a) providing isolated cord blood stem cells by:

i) performing machine perfusion of an isolated mammalian placenta comprising cord blood comprising cord blood stem cells, said performing machine perfusion being done with a pressure mediated pulsatile flow of a perfusion solution to produce a perfusate comprising cord blood comprising cord blood stem cells, wherein said isolated mammalian placenta is non-exsanguinated;

ii) collecting the perfusate; and

iii) isolating the cord blood stem cells from the perfusate to produce isolated cord blood stem cells; and

b) introducing into a mammal comprising a damaged tissue a composition comprising a therapeutically effective amount of cells selected from the group consisting of the isolated cord blood stem cells and cells derived therefrom, whereby the damaged tissue is treated.

2. A method according to claim 1 , wherein said introducing comprises: introducing into the mammal a composition comprising a therapeutically effective amount of the isolated cord blood stem cells.

3. A method according to claim 1 , wherein said introducing comprises: obtaining said cells derived therefrom by culturing in vitro the isolated cord blood stem cells, thereby producing said cells derived therefrom; and introducing into the mammal a composition comprising a therapeutically effective amount of said cells derived therefrom.

4. The method according to claim 3 , wherein said cells derived therefrom are expanded stem cells.

5. The method according to claim 1 , wherein said introducing comprises introducing into the mammal intravenously or by direct injection into the damaged tissue a composition comprising a therapeutically effective amount of cells selected from the group consisting of isolated cord blood stem cells and cells derived therefrom.

6. The method according to claim 5 , wherein the tissue comprises one or more of cardiac tissue, muscle tissue, liver, skin, neural tissue, bone tissue, epithelia, stroma, or endothelium.

7. A method for treating a mammal comprising a damaged tissue, comprising:

(a) optionally culturing in vitro isolated cord blood stem cells, thereby producing expanded stem cells, said isolated cord blood stem cells being obtained by:

i) performing machine perfusion of an isolated mammalian placenta comprising cord blood comprising cord blood stem cells,

said performing machine perfusion being done with a pressure mediated pulsatile flow of a perfusion solution to produce a perfusate comprising cord blood comprising cord blood stem cells,

wherein said isolated mammalian placenta is non-exsanguinated;

ii) collecting the perfusate; and

iii) isolating the cord blood stem cells from the perfusate to produce isolated cord blood stem cells; and

(b) introducing into a mammal comprising a damaged tissue a composition comprising a therapeutically effective amount of cells selected from the group consisting of:

i) said isolated cord blood stem cells;

ii) said expanded stem cells, and

iii) combinations thereof;

whereby said damaged tissue is treated.

8. A method for treating a mammal comprising a damaged tissue, comprising:

a) providing isolated cord blood stem cells by:

i) providing an isolated mammalian placenta comprising cord blood comprising cord blood stem cells, wherein said isolated mammalian placenta is partially exsanguinated to produce a volume of cord blood comprising a first population of isolated cord blood stem cells;

ii) conducting machine perfusion of the isolated mammalian placenta with a pressure mediated flow of a perfusion solution to produce a perfusate comprising cord blood comprising cord blood stem cells, wherein said machine perfusion is performed using a pump;

iii) collecting the perfusate; and

iv) isolating the cord blood stem cells from the perfusate to produce a second population of isolated cord blood stem cells; wherein said second population of isolated cord blood stem cells has a greater percentage of CD 133+ cells than said first population of isolated cord blood stem cells; and

b) introducing into a mammal comprising a damaged tissue a composition comprising a therapeutically effective amount of cells from the second population of isolated cord blood stem cells or cells derived from the second population of isolated cord blood stem cells, whereby the damaged tissue is treated.

9. A method according to claim 8 , wherein said introducing comprises: introducing into the mammal a composition comprising a therapeutically effective amount of cells from the second population of isolated cord blood stem cells.

10. A method according to claim 8 , wherein said introducing comprises: obtaining said cells derived therefrom by culturing in vitro cells from the second population of isolated cord blood stem cells, thereby producing said cells derived from the second population of isolated cord blood stem cells; and introducing into the mammal a composition comprising a therapeutically effective amount of said cells derived from the second population of isolated cord blood stem cells.

11. A method according to claim 8 , wherein said introducing comprises introducing into the mammal a composition comprising a therapeutically effective amount of cells from the second population of isolated cord blood stem cells, said composition further comprising cells from the first population of isolated cord blood stem cells.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2025
From: CELULARITY INC.
To: CELENIV PTE. LTD.
Reel/Frame 073705/0109 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2017
From: CELULARITY BIOSOURCING, LLC
To: CELULARITY, INC.
Reel/Frame 044098/0717 →
CHANGE OF NAME Recorded Nov 9, 2017
From: HLI CELLULAR THERAPEUTICS, LLC
To: CELULARITY BIOSOURCING, LLC
Reel/Frame 044707/0351 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2016
From: ANTHROGENESIS CORPORATION, A NEW JERSEY CORPORATION, D/B/A CELGENE CELLULAR THERAPEUTICS
To: HLI CELLULAR THERAPEUTICS, LLC, A DELAWARE LIMITED LIABILITY COMPANY
Reel/Frame 039411/0443 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2015
From: CORD BLOOD SCIENCE LLC
To: ANTHROGENESIS CORPORATION
Reel/Frame 036818/0850 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2012
From: TAKEBE, NAOKO
To: CORD BLOOD SCIENCE INC.
Reel/Frame 029438/0648 →